Regeneron Pharmaceuticals (REGN) has been under the radar as it delivered impressive returns to investors with a 220% increase over the last five years. Despite market fluctuations, the firm's stock consistently outperformed its competitors. Sierra Summit Advisors and Oracle Alpha made new investments, highlighting strong investor confidence. REGN's CEO shared positive remarks on their financial health based on strong trading days, adding to the bullish sentiment. However, a setback was seen with the FDA raising concerns about their blood cancer therapy, and the US accusing them of fraudulent price reporting for their eye drug. Apart from these, there has been optimistic chatter among investors regarding possible undervaluation of the firm at 42% and 47%. The firm sees future growth in gene editing therapies with their collaboration with Mammoth. However, concerns over the CEO selling off a significant number of shares and alleged fraudulent practices related to their leading product Eylea have caused some investors to express caution. A potential debacle with their drug Dupixent's FDA approval for 'Smoker's Lungs' Disease' is currently under review.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 08 Sep 2023 07:00:00 GMT to Sun, 16 Jun 2024 11:58:28 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -2
